7364-27-4

Basic information

• Product Name: 5-BROMO-3-HYDROXY (1H)INDAZOLE
• Synonyms: 5-BROMO-3-HYDROXY (1H)INDAZOLE;5-BROMO-1,2-DIHYDRO-INDAZOL-3-ONE;5-BROMO-3-HYDROXYINDAZOLE;5-Bromo-1H-indazol-3-ol;3H-Indazol-3-one, 5-broMo-1,2-dihydro-;5-broMo-1,2-dihydro-3H-Indazol-3-one
• CAS NO: 7364-27-4
• Molecular Formula: C₇H₅BrN₂O
• Molecular Weight: 213.03
• Mol File: 7364-27-4.mol

Chemical Properties

• Boiling Point: 209.098 °C
• Flash Point: 209.098°C
• Appearance: /
• Density: 1.942 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.784
• Storage Temp.: 2-8°C
• PKA: 11.02±0.20(Predicted)
• CAS DataBase Reference: 5-BROMO-3-HYDROXY (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-3-HYDROXY (1H)INDAZOLE(7364-27-4)
• EPA Substance Registry System: 5-BROMO-3-HYDROXY (1H)INDAZOLE(7364-27-4)

Safety Data

• Hazardous Substances Data: 7364-27-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Bromo-3-hydroxy (1H)indazole is used as an intermediate in the synthesis of pharmaceuticals and organic compounds. Its unique structure and functional groups make it a valuable building block for the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-Bromo-3-hydroxy (1H)indazole is utilized for its wide range of biological activities. Its anticonvulsant properties make it a promising candidate for the development of treatments for epilepsy and other seizure disorders.
Used in Drug Discovery:
5-Bromo-3-hydroxy (1H)indazole's antifungal properties contribute to its potential as a lead compound in the discovery of new antifungal agents. This could be particularly beneficial in addressing the growing issue of drug-resistant fungal infections.
Used in Antifungal Applications:
5-Bromo-3-hydroxy (1H)indazole is used as an antifungal agent for its ability to inhibit the growth of various fungi. This makes it a valuable compound in the development of new antifungal drugs to combat infections caused by fungi.
Used in Anticonvulsant Applications:
5-Bromo-3-hydroxy (1H)indazole is used as an anticonvulsant agent for its potential to treat conditions characterized by abnormal electrical activity in the brain, such as epilepsy and other seizure disorders. Its effectiveness in reducing seizure activity highlights its potential as a therapeutic agent in this area.

InChI:InChI=1/C7H5BrN2O/c8-4-1-2-6-5(3-4)7(11)10-9-6/h1-3H,(H2,9,10,11)

Upstream product

• 141122-59-0 3-(4-Bromo-2-carboxyphenyl)sydnone 
• 32253-75-1 5-bromo-2-<(carboxymethyl)amino>-benzoic acid 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 177192-82-4 C₇H₇BrN₂O₂ 
• 7364-25-2 3-indazolinone 
• 146328-85-0 5-bromo-2-fluoro-benzoic acid 
• 445-29-4 o-fluoro-benzoic acid 
• 57381-59-6 methyl 2-fluoro-5-bromobenzoate 

Downstream Products

• 1096711-81-7 C₂₁H₁₅BrClN₃O₄S 
• 1096711-82-8 C₂₁H₁₄Br₂ClN₃O₄S 
• 1096711-88-4 C₁₉H₁₃BrN₄O₂S 
• 1096711-95-3 C₂₃H₁₆BrN₃O₄S 
• 1096711-83-9 C₁₈H₁₆BrN₃O₅S 
• 1096711-89-5 C₁₉H₁₃BrN₄O₂S 

Relevant articles and documents

Discovery of isatin and 1H-indazol-3-ol derivatives as D-amino acid oxidase (DAAO) inhibitors

D-Amino acid oxidase (DAAO) is a potential target in the treatment of schizophrenia as its inhibition increases brain D-serine level and thus contributes to NMDA receptor activation. Inhibitors of DAAO were sought testing [6+5] type heterocycles and identified isatin derivatives as micromolar DAAO inhibitors. A pharmacophore and structure-activity relationship analysis of isatins and reported DAAO inhibitors led us to investigate 1H-indazol-3-ol derivatives and nanomolar inhibitors were identified. The series was further characterized by pKa and isothermal titration calorimetry measurements. Representative compounds exhibited beneficial properties in in vitro metabolic stability and PAMPA assays. 6-fluoro-1H-indazol-3-ol (37) significantly increased plasma D-serine level in an in vivo study on mice. These results show that the 1H-indazol-3-ol series represents a novel class of DAAO inhibitors with the potential to develop drug candidates.

TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, codrug, cocrystal, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the u

PHARMACEUTICALS CONTAINING NOVEL 1-POSITION SUBSTITUTED INDAZOLE DERIVATIVE

PROBLEM TO BE SOLVED: To provide pharmaceuticals containing a compound having strong effect of modulating α7 nicotinic acetylcholine receptor (α7nAChR) and useful as treatment agent for diseases related to cholinergic in central nervous system (CNS) and/o

NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE

A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimics

The discovery and initial optimization of a novel anthranilic acid derived class of antibacterial agents has been described in a recent series of papers. This paper describes the discovery of 1-acylindazol-3-ols as a novel bioisostere of an anthranilic acid. The synthesis and structure-activity relationships of the indazol bioisosteres are described herein.

NEW CONVENIENT METHODS FOR THE SYNTHESIS OF 1,2-DIHYDRO-3H-INDAZOL-3-ONE AND ITS 1-ACYL DERIVATIVES

The acid hydrolysis of the readily obtainable 3-(o-carboxyphenyl)sydnones (6a-d) afforded 3-indazolones (3a-d) in yields over 90 percent. By transacylation between 1-acyl-3-acyloxyindazoles (11a-d) and 3-indazolones (3a, c), the corresponding 1-acyl-3-indazolones 10a-d resulted in pure state and yields also over 90 percent.

The Structure of Indazolinone and Derivatives in the Solid State and in Solution: an X-Ray and Nuclear Magnetic Resonance Study

The structure of indazolinone and some of its derivatives was obtained by the combined use of crystallography, 13C CP/MAS, and 15N n.m.r.It was concluded that indazolinone exists as such in the solid state but only as a minor tautomer (15percent) in DMSO solution, where the 3-hydroxyindazole tautomer predominates (85percent).The result of bromination of indazolinone is reported.Two acylhydrazines, as open analogues of indazolinone, were studied as model compounds.